FDA Approves New Type 2 Diabetes Drug
Although living with diabetes can seem like a very isolating thing, the American Diabetes Association says that some 2.5 million individuals in the United States alone have the disease; the majority of those being treated have Type 2 diabetes. Because of the growing numbers of patients with this chronic illness, pharmaceutical companies and researchers are constantly looking for new methods of treatment and new medicines. For type one diabetics, insulin is absolutely necessary for health, which is a fairly straightforward medicine, requiring those patients to purchase Easytouch insulin syringes, or insulin pen needles, or possibly even insulin pump supplies regularly. For type two diabetics, in addition to other diabetic supplies (in some cases including insulin), there are other medications that come into play. Unfortunately, these medications tend to have a number of side effects associated with them. Recently, the FDA approved a new medicine that may eliminate some of the side effects associated with traditional medications.
The medicine was co-developed by Bristol-Myers Squibb Co and AstraZeneca. Late last year, AstraZeneca bought out Bristol’s stake in their diabetes joint venture for more than $4 billion, including upfront and sales-related milestone payments. The medication is to be called Farxiga, and is one of a new class of medicines for treating type 2 diabetes called sodium-glucose co-transporter 2 inhibitors. While most medicines Type 2 diabetes work to decrease insulin resistance in the body, or to increase the amount of insulin in the body, Farxiga uses a different mechanism for removing excess sugar from the blood. Some patients with Type 2 diabetes take insulin already, using an insulin syringe like the easytouch insulin syringe, or insulin pen needles or an insulin pump. Most patients with Type 2 diabetes also take pills such as Metformin. Faxiga removes excess glucose from the blood by blocking kidney reabsorption and increasing the excretion of sugar in the urine.
In addition to helping diabetics rid their body of excess sugar, the drug also showed promise in helping individuals with Type 2 diabetes to lose weight. The medicine Farxiga has been in use in Europe, but had previously stumbled when the companies responsible for its development submitted it for FDA approval. The FDA had initially rejected the Astra and Bristol-Myers drug in early 2012 over concerns about possible cancer and heart risks. The companies provided additional data that addressed those concerns to the satisfaction of the advisory panel and the agency. Although it has been approved, the FDA is still requiring a post-marketing study to follow up on the potential for cardiovascular risks. However, the drug is showing a great deal of promise and may be a solution to many individuals having difficulty treating diabetes on previously-existing medications, including type 2 diabetics who use insulin in the form of taking it by Easytouch insulin syringe, insulin pen needles, or insulin pump. Medical professionals are excited about the potential for the new medicine and what it could mean for improving the quality of life of their patients. The next time you visit your doctor for a checkup, you may want to discuss the new medication, as well as discussing all other forms of treatment for your disease.
- What Diabetes Supplies Should You Purchase? 29.02.2016